ABSTRACT: This study was undertaken to screen periprosthetic tissues (PPTs) under specified conditions for a series of molecular components and describe them in bone remodeling processes within aseptic loosening. PPT samples were obtained from patients undergoing revision surgery of endoprostheses (n ¼ 24) and synovial tissues from patients with OA (control) (n ¼ 18), patients with any form of inflammatory arthritides were excluded. Tissue samples were examined via microbiology, histology (H&E, TRAP), immunohistochemistry (CD68/anti-S100a4), quantitative real-time PCR (ALP, COL1A1, cathepsin K, M-CSF, MMP13, OPG, RANK, RANKL, TNF-a, and TRAP) and an endotoxin-assay. PPT samples contained a variety of cellular components and stained positive for TRAP (56%), CD68 (100%), and S100a4 (100%). Wear debris were found in cells staining positive for CD68 and S100a4. In PPTs significantly higher ALP, COL1A1, MMP-13, RANK, RANKL, and TRAP expression were found along with a significantly higher RANKL/OPG ratio and a significantly lower OPG expression. No significant difference was observed for M-CSF, TNF-a, cathepsin K, and endotoxin levels. In conclusion we found osteogenic proteins (ALP, COL1A1), a proteolytic enzyme (MMP-13), markers for osteoclast differentiation (RANK, RANKL), and osteoclast activity (TRAP) to be increased in PPT, whereas OPG expression decreased significantly in comparison to control. We present data about a large series of molecular components in PPT and describe novel and key findings about their expression levels in regards to aseptic implant loosening. ß
Aseptic loosening is the most common late failure cause of artificial joint replacement. The current paradigm to explain periprosthetic osteolysis involves an inflammatory response to wear particles produced by implants, first described in 1977. 1 Wear particles are phagocytosed by cells adjacent to implants, resulting in cell activation and a release of cytokines. Osteoclast differentiation starts after NF-kB-Ligand (RANKL) binds on the receptor activator NF-kB (RANK) expressed by osteoclast precursors under the presence of macrophage-colony stimulating factor (M-CSF). Dysregulation of the osteoclast-osteoblast coupling in favour of osteoclasts and of the RANKL-RANK-OPG axis leads to net bone resorption in periprosthetic osteolysis.
In PPTs an increase in RANKL/OPG ratio 2-5 compared to both synovial tissue from patients with osteoarthritis (OA) [3] [4] [5] as well as synovial tissue from patients with fracture of the femoral neck 2 have been described. Osteoprotegerin (OPG), the decoy receptor which binds RANKL and thus inhibits the RANKL-RANK interaction, has been observed to be downregulated in aseptic loosening. 3, 4, 6 However, the molecular pathogenesis of periprosthetic osteolysis is multifactorial. Matrix metalloproteinases (MMPs), which enhance osteolysis by degradation of the collagen matrix, are upregulated in aseptic loosening. 7, 8 Cytokines like M-CSF 6,9 and tumornecrosis factor-a (TNF-a) 10 are described to be potentially involved in bone remodeling. Tartrateresistant acid phosphatase (TRAP) and cathepsin K, both markers for osteoclast activity, have been observed to be elevated in aseptic loosening. 3, 6 Osteoblasts, which express collagen type 1A1 (COL1A1) and alkaline phosphatase (ALP) have been shown to be among the cells which participate in aseptic loosening. Endotoxin plays a role in particle induced implant loosening by stimulating the cytokine production and osteoclast differentiation. 11 Literature provides a series of studies, using different molecular components of PPTs, resulting in the classification of various "key proteins" for aseptic loosening. Synopses of these studies on molecular analyses concede limitations. 12, 13 Using OA synovial tissue as control is commonly designated as the "gold standard," 12 however individual inclusion and exclusion criteria of patients with OA are chosen. The quality of control tissues might provide an answer for the large variance of the data. In order to obtain control tissues with minimal interference factors, patients with any form of inflammatory arthritides were excluded from this study.
To further evaluate PPTs a screening profile for a wide range of molecular components regulating osteoclast formation from selected patients with OA was performed. The aim of the study was to analyse osteoclastogenic regulators (RANK, RANKL, and OPG), markers for osteoclastogenesis (TRAP), proteolytic enzymes (cathepsin K, MMP 13), cytokines (M-CSF, TNF-a), osteogenic proteins (ALP, COL1A1), and endotoxin levels in PPTs and control tissues under specified conditions and describe their expression levels in bone remodeling processes within aseptic loosening. We hypothesized that a screen of molecular components including a variety of markers under specified conditions excluding inflammatory arthritides might clarify the characteristics of PPTs compared to synovial tissues from patients with OA.
MATERIALS AND METHODS
Patients PPT samples were obtained from patients undergoing revision surgery of hip (THA, n ¼ 15, 5 male, 10 female) or knee (TKA, n ¼ 9, 4 male, 5 female) endoprostheses due to aseptic loosening initially performed for primary OA with the mean age of 69 years (range 45-88). Time to revision surgery varied between 2 years, 2-10 years and !10 years (each subgroup n ¼ 8). As control, synovial tissue samples obtained from patients undergoing hip replacement surgery due to primary OA, (n ¼ 18, 9 male, 9 female) with mean age of 67 years (range 45-86) were collected. The diagnosis of hip and knee OA was based on the American college of Rheumatology criteria. The study was approved by the responsible LudwigMaximilians-University medical center ethics committee. Patients are described in Table 1 . Patients with rheumatoid arthritis or other inflammatory arthritides or any other auto immune disease were excluded on the basis of patient history, radiological and laboratory data. Septical loosening was excluded by microbiological cultures performed at the Department of Microbiology of the Ludwig-Maximilians-University of Munich. For RNA isolation, tissue samples were immediately snap-frozen and stored in À80˚C, for histology, tissue samples were fixed in 4% paraformaldehyde.
Tissue Preparation
Samples were fixed in 4% paraformaldehyde (Merck, Darmstadt, Germany) for 24 h and then decalcified in 15% EDTA (DCS Innovative, Hamburg, Germany), pH 8.0. After embedding in paraffin, samples were cut into 6 mm sections and mounted on superfrost glass slides (Menzel, Braunschweig, Germany). Staining was performed after deparaffinization in xylol (Roth, Karlsruhe, Germany) and rehydration in graded alcohol series.
HE and TRAP Staining
All samples were stained with Mayer's Haemalaun/Eosin (Merck, Darmstadt, Germany) and embedded in Eukitt (Sigma-Aldrich Co., St. Louis, MO). Detection of tartrateresistant acid phosphatase (TRAP) was performed using a commercial kit (Sigma-Aldrich Co.). Sections were then embedded in Aquamount (Merck, Darmstadt, Germany).
Immunohistochemistry
For the detection of CD68-antigen, anti-CD68 PG-M1 antibody (Dako, Glostrup, Denmark, M0876), a pan-macrophage marker, was used on serial sections.
The antigen was first unmasked by treatment with proteinase XXVI (Sigma-Aldrich Co.) 0.1% in phosphate buffered saline (PBS) (Merck, Darmstadt, Germany) for 10 min at 37˚C. After washing twice (always in PBS with 0.2% Tween (Merck Schuchardt, Hohenbrunn, Germany) for 5 min), the endogenous peroxidase was blocked with 0.1% hydrogen peroxide (Merck, Darmstadt, Germany) in PBS for 10 min at room temperature (RT) followed by another washing step. Then sections were incubated with a mixture of ABO-Serum (Biotest, Dreieich, Germany) and horse serum (Vector Laboratories, Burlingame, CA), both 1:20 in PBS with 3% BSA, for 1 h at RT.
Following the pretreatment, sections were incubated over night at 4˚C with anti CD68 PG-M1 1:100 in antibody dilution buffer (ADB)(DCS Innovative, Hamburg, Germany). For negative controls, the first antibody was omitted. After washing, sections were incubated with biotinylated horse anti mouse (Vector Laboratories) 1:200 in ADB for 30 min at RT. Following washing sections were treated with a avidinbiotin-peroxidase complex (ABC) (Vector Laboratories) for 30 min at RT. After a final washing step, the sections were stained with 3.3 0 Diaminobenzidine (DAB) (Vector Laboratories), counterstained with Haemalaun and mounted in DPX (Sigma-Aldrich).
For monolabeling the fibroblast like cells the polyclonal antibody anti-S100a4 ab27957 (Abcam, Cambridge, UK) was used. A heat induced retrieval method was performed in order to unmask the antigen as follows: The sections were steamed in a citrate buffer pH 6.0 (DCS Innovative, Hamburg, Germany) for 25 min (BRAUN FS 20 Multiquick Steamer, Kronberg, Germany), then left to cool. After washing, the blocking of unspecific binding sites was implemented with ABO-and horse serum as described above.
The labeling process began with the application of antiS100a4 (1:100 in ADB) and incubation at RT for 1h. For negative controls, the first antibody was omitted. Super vision 2 polymer kit (DCS Innovative, Hamburg, Germany) was used to visualize the staining: sections were treated with an anti-mouse, anti-rabbit coupled enhancer for 30 min at RT. After washing, incubation with an alkaline phosphatase labeled polymer for 30 min at RT was performed, followed by another rinsing step. PermaRed Chromogen (DCS Innovative, Hamburg, Germany) was then used as detection substance. After 5 min at RT the reaction was stopped in aqua dest. The sections were counterstained with Heamalaun and mounted in DPX.
For dual labeling, sections were treated with anti-CD68 PG-M1 and anti-S100a4. Heat induced unmasking of the THA, total hip arthroplasties; TKA, total knee arthroplasties.
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antigen and the blocking of unspecific binding sites were performed as described above. After washing, sections were treated with 0.1% proteinase XXVI for 10 min at RT. Following another washing step the endogenous peroxidase was blocked with 0.1% hydrogen peroxide (Merck, Darmstadt, Germany) in PBS for 10 min at RT. After incubation with anti-S100a4 for 1h at RT the polymer kit was applied as above. Sections were washed and incubated with anti-CD68 PG-M1 over night at 4˚C. The staining was completed as stated in the CD 68 monolabeling protocol.
Quantitative Real-Time PCR For gene expression tissue was disrupted under frozen conditions at 3000 rpm by a Micro-Dismembrator S (Sartorius, G€ ottingen, Germany and TRAP. 16 Primer sequences are shown in Table 2 . The amplification reactions were performed with the Light Cycler 1 FastStart Essential DNA Green Master (Roche Diagnostics, Mannheim, Germany). A 2.5 ml of the 1:3 diluted sample was either mixed using 0.3 ml Primer and 2.2 ml water for 300 nM or 0.5 ml of primer and 2 ml water for 500 nM concentration. Five microliter FastStart Essential Green Master was added to both concentrations. Mixed samples were preincubated at 95˚C for 10 min. The amplification protocols and concentrations for each primer are shown in Table 2 . Reactions were performed in triplicates. For the relative quantification, samples were normalized against GAPDH. A subgroup analysis of PPTs was performed which was separated according to time of revision surgery including the subgroup 2 years, the subgroup 2-10 years and the subgroup ! 10 years.
Endotoxin-Assay
Tissue samples < 10 mg were disrupted under frozen conditions at 3,000 rpm by a Micro-Dismembrator (Sartorius, G€ ottingen, Germany). The dismembrator ball (chromium steel, Sartorius, G€ ottingen, Germany) was preheated at 250˚C for 30 min to eliminate endotoxin. The frozen milled samples were solved in 1 ml of LAL reagent water (Lonza, Basel, Switzerland) for 60 min at RT on a shaker (Certomat MO II, Sartorius, G€ ottingen, Germany). Then samples were centrifuged with 600g for 10 min. The supernatant was transferred and heated by 100˚C for 10 min. The Limulus amebocyte lysate (LAL) kinetic chromogenic assay (sensitivity ¼ 0.005 EU/ml) was performed by Lonza (Verviers, Belgium). Each sample was tested at 1/1, 1/10, and 1/100 dilution with a positive product control (PPC) of 0.5 endotoxin U/ml. The protocol was modified according to Nalepka et al. 20 in order to exclude the possibility of false positives due to nonspecific amidases.
Statistical Analysis
Graph Pad Prism 5.01 (GraphPad Software, La Jolla, CA) was utilized to analyse the data. Statistical inferences were based on Mann-Whitney U tests for two-group comparisons and Kruskal-Wallis tests in case of three comparison groups. p values <0.05 were regarded as significant. Due to the exploratory character of our analyses we abstained from alpha corrections for multiple testing. Thus, the test results must not be mistaken as confirmatory. 
RESULTS
Histology
The histological examination showed PPT tissues contain a variety of cellular components. All PPT and control tissues stained positive for CD68 and S100a4. No differences in the general appearance were observed between TKA and THA as well as between specimens from cemented and uncemented prostheses.
TRAP positive multinucleated cells were detected in 56% of PPT samples and in 16% of control samples. TRAP positive cells (Fig. 1A) also stained positive for CD68 in serial sections (Fig. 1B) and were surrounded by fibroblast like cells, which stained positive for S100a4 (Fig. 1C) . Wear debris were found in cells staining for CD68 ( Ã ) and in S100a4 positive cells (arrow) (Fig. 2) . There was no significant difference for TRAP staining between TKA (67%) and THA (53%) and between cemented (57%) and uncemented (60%) samples.
mRNA Profile of PPTs Compared to Control
Expression levels of the proinflammatory cytokines M-CSF and TNF-a tended to be higher in PPTs compared to control, however there was no statistical significance ( Fig. 3A and B) .
Significantly higher mRNA levels were found for RANK (p < 0.0001) (Fig. 3C) and RANKL (p ¼ 0.0013) (Fig. 3D) in the PPTs compared to the control levels. OPG, the decoy receptor of RANKL, presented a significant lower (p < 0.0001) expression in PPTs compared to control (Fig. 3E) . TRAP was significantly higher expressed in PPTs compared to the control (p < 0.0001) (Fig. 3F) . Another osteoclast marker, cathepsin K showed no significant difference in PPTs compared to control (Fig. 3G ). Significantly higher (p ¼ 0.0004) expression levels in PPT compared to the control were detected for MMP-13 (Fig. 3H ). For ALP (p ¼ 0.0002) as well as COL1A1 (p ¼ 0.0095) significant higher mRNA expression levels were observed in PPTs compared to control (Fig. 3I and K) .
The subgroup analysis of PPTs for primers showed highest expression of ALP, COL1A1, RANK, RANKL and TNF a in the subgroup with time to revision surgery 2 years and of MMP-13 and TRAP in the subgroup ! 10 years. M-CSF showed the highest expression in the subgroup 2-10 years. OPG did not show any significant expression changes within PPT tissues regarding time of revision surgery (Fig. 4) .
A significantly higher mean RANKL/OPG ratio (p < 0.0001) was found in PPTs compared to the control samples (Fig. 5) , while the subgroup analysis of PPTs showed no significant differences in RANKL/ OPG Ratio (Fig. 6 ).
Endotoxin Testing
Results of the LAL kinetic chromogenic assay are presented for 1/1 dilutions, having the highest spike recovery rate. No significant differences between PPTs and control samples were found (Fig. 7) There was also no significant difference observed in the subgroup analysis of endotoxin values between PPTs (Fig. 8) . In 42% of the PPT samples and 56% of the control samples endotoxin levels over 0.005 EU/ml were detected. As positive control a defined positive product control of 0.5 endotoxin U/ml was used. 
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This study revealed a significantly higher ALP, COL1A1, MMP-13, RANK, RANKL, and TRAP expression and a significantly lower OPG expression in PPTs compared to the control samples. Moreover, PPTs showed a significant increase in the RANKL/ OPG ratio. Comparing the expression of M-CSF, TNF-a, cathepsin K, and endotoxin levels no signifi- cant differences were observed between PPTs and control tissues. An increased RANKL/OPG ratio was found to be critical for osteolysis in several bone destructive processes 21 and has been described for PPTs. [2] [3] [4] [5] 22 The increased ratio was either due to a higher RANKL level 2, 5 or lower OPG level. [3] [4] [5] [6] This is the first study to describe both significant RANKL up-and OPG down- regulation in PPTs. Regarding RANKL lowest expression levels have been described in "healthy" subjects undergoing arthroscopy, when compared to synovial tissues from OA subjects or to PPTs. 5 RANKL upregulation is connected with increased bone turnover in periprosthetic osteolysis.
2,5-7,22-24 RANKL is of multicellular origin, being expressed by osteoblasts, bone marrow stromal cells, fibroblasts, lymphocytes, mast cells and macrophages in PPTs. 5, 12 Dual labeling with CD68 and RANKL indicated that macrophages and monocytes were the main binding site for RANKL, although the cell source has not been fully verified. 5 RANKL expression was localized to cells that stained positive for fibroblast markers in PPTs. 24 According to literature and our results the presence and elevated expression suggests an important role of RANKL in aseptic loosening. Regarding OPG decrease 3, 4, 6 or stable expression 2,5 literature has described the occurance of both for periprosthetic osteolysis. In the current study OPG was significantly reduced in expression compared to the control. OPG is expressed by endothelial cells lining small blood vessels in PPTs 5 and has been described to also be expressed by periprosthetic fibroblasts. 10 Osteoblasts exposed to polyethylene particles produce less OPG. 25 OPG is among the key regulators of osteolysis as it blocks the maturation of osteoclasts. OPG downregulation in PPTs supposably suggests that OPG decompensates to act as protective mechanism of the skeleton. The ratio of RANKL/OPG might thereby be related to the size of the osteolytic defect. 26 Within this study the expression level of RANK, which is expressed on the surface of precursors and mature osteoclasts, was found to be significantly upregulated in PPTs, similar to descriptions in literature. 2 TRAP, a marker for osteoclast activity, was also found significantly increased, which has been described for PPTs. 3, 6 RANK and TRAP represent the osteoclastic lineage that plays a key part in implant loosening.
For cathepsin K, another marker of osteoclast lineage, expression was shown to be predominant but not significantly increased in PPTs within this study. In literature, cathepsin K expression was described to be upregulated in PPTs versus control. 3, 6 Cathepsin K, which has also been detected in macrophages, giant cells 13 and in periprosthetic fibroblasts 27 of PPTs is active at a low pH and plays a major role in osteoclast bone resorption. However, the bone matrix is degraded not only by cathepsin K but also by MMPs. An increased MMP production in PPTs leads to pathologic tissue destruction by increased collagen degradation around a loosened implant. 8 In this study a significant upregulation of MMP-13 in PPTs was observed, which confirms former findings of expression regulation in PPTs. 7 Periprosthetic fibroblasts are one of the main sources of MMPs found in PPTs. 28 Periprosthetic fibroblasts, which have also been shown to express RANKL and OPG 10 in PPTs, are assumed to play an important role in aseptic loosening. It is not clear whether the role of cathepsin K or MMPs predominates in aseptic implant loosening.
M-CSF has been described to be upregulated in PPTs 6 where it has been detected in macrophages, fibroblasts and vascular endothelial cells. 9 In our study M-CSF was predominantly found in PPTs although no significant difference of expression levels was observed to control. Macrophages exposed to M-CSF assume an anti-inflammatory phenotype known as alternative macrophage activation or M2 polarization. 29 M-CSF would therefore have been expected to contribute to M2 polarization in periprosthetic tissues. However, in PPTs macrophage phenotypes are supposed to be regulated by other local and systemic factors than the traditional macrophage polarizing cytokines.
6 M-CSF is also produced constitutively during stimulation of osteoclast differentiation by the increased RANKL/OPG ratio. 30, 31 M-CSF as a macrophage activating factor therefore plays a role in aseptic loosening but might not be among the key regulators like RANKL and OPG.
The proinflammatory cytokine TNF-a, which is expressed by monocytes and macrophages in PPTs, 32 has to be taken into account separately. TNF-a is considered a key inflammatory cytokine involved in the pathophysiology of OA. 33 Macrophages increase their expression of TNF-a when they are treated with polyethylene particles. 34 Apart from that TNFa plays a prominent role in the pathogenesis of the immune-mediated inflammatory diseases. We observed no significant difference in the expression levels of TNF-a, although TNF-a was predominantly expressed in PPTs. TNF-a expression however, showed significant differences in the subgroup analysis with highest expression values in the subgroup with time to revision surgery 2 years. Similar findings were reported in a comparative PPT versus control study, where patients with rheumatoid and inflammatory OA were excluded. 6 This is in contrast to data where significantly higher TNF-a expression levels were observed in OA synovial tissues compared to PPTs. 4 We assume that increased TNF-a expression in control OA tissues might be due to an overrepresentation of inflammatory diseases within the population. The exclusion of patients with rheumatoid, inflammatory OA and autoimmune diseases could be recommended as an "improved gold standard" in comparative studies to exclude altered expression levels caused by inflammatory diseases. TNF-a expression might be an indicator of inflammatory diseases, which play a role in periprosthetic loosening.
According to current paradigms periprosthetic osteolysis is the end result of a cascade generated by a variety of different cell types in response to wear particles. Osteoblasts are among the cell types that play a role in aseptic loosening, as they are responsible for bone formation. Osteoblasts secret components of the extracellular matrix including COL1A1, which forms 90% of the extracellular matrix. 35 Particulate wear debris was shown to downregulate COL1A1 synthesis in osteoblasts. 36, 37 Polyethylene particles induced a switch in osteoblasts from promoting COL1A1 production (anabolic phenotype) to inducing the expression of pro-osteoclastic genes (catabolic phenotype) in vitro. 25 Osteoblastic markers would therefore have been expected to be decreased. However, within this study a significant upregulation of COL1A1 expression in PPTs was observed, which has not been described before. The upregulation of COL1A1 is accompanied by a significant upregulation of ALP, which is a further new and important finding. ALP expression would have been expected to be equally reduced, as ALP activity is reduced in osteoblasts under the influence of metal ions. 38 Our in vivo results from PPTs showed, for the first time, that ALP and COL1A1 might undergo another regulatory mechanism in aseptic loosening than in the in vitro setups examining wear response on osteoblasts. ALP has been described to be upregulated in human mesenchymal stem cells under the influence of particles.
14 ALP production might therefore have increased due to an upregulation within mesenchymal stem cells or other cell components found in PPTs. It might be of general clinical importance to re-evaluate ALP and COL1A1 expression in periprosthetic loosening, as ALP plays an important role in the bone remodeling processes and COL1A1 is the major extracellular matrix component of bone.
The subgroups were chosen in a modified form according to the revised consensus classification of diseases associated with joint endoprosthesis using merely the time to revision surgery, which closely refers to the neosynovialis type 39 ( 2 years, type II, infectious type; 2-10 years, type II and IV, mixed and indifferent type; !10 years, type I, wear type). The subgroup analysis showed highest expression of ALP, COL1A1, RANK, RANKL, and TNF-a in the subgroup with time to revision surgery 2 years and of cathepsin K, MMP-13 and TRAP in the subgroup ! 10 years. M-CSF showed the highest expression in the subgroup 2-10 years. OPG, RANKL/OPG and endotoxin did not show any significant expression changes within PPT tissues regarding time of revision surgery.
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Although there are limitations for a solely time to revision surgery related subgroup analysis, it might be assumed that the time to revision surgery also gives an answer about the condition within PPTs. Although it is speculative we postulate that for implants with time to revision surgery 2 years an anabolic inflammative condition prevails, in which ALP and COL1A1 are overproduced and RANK, RANKL and TNF-a play an important role. Clinically, little osteophyte formation and therefore little osteoblastic activity, has been shown to be one of the risk factors for early aseptic failure. 40 An increased osteoblastic activity after arthroplasty, which is associated with osseointegration, is therefore somehow unlikely to be part of the osteolytic process. However, active bone formation, regarded as repair process, is the most common feature in revised arthroplasties. 41 PPTs from implants with time to revision surgery ! 10 years mainly present with a catabolic condition, where finally MMP-13 and TRAP tend to become the major players in aseptic loosening. OPG and RANKL/OPG, however, did not show any significant changes of expression values within the subgroups and was permanently detected at a very low level. The permanently stable low OPG levels render OPG further importance of function within aseptic loosening. Endotoxin values also did not deviate significantly between the subgroups. Endotoxin has been described to play a major role in aseptic loosening as adherent endotoxin on wear particles stimulates cytokine production and osteoclast differentiation. 11, 42 As to our knowledge there exists no direct comparison of endotoxin levels between PPTs and controls of any kind. This study examined endotoxin levels according to a modified protocol to exclude the possibility of false positives due to nonspecific amidases. 20 For endotoxin levels there was no significant difference observed between the control and PPTs. Significant higher endotoxin levels were described in PPTs from patients with inflammatory arthritis than from patients with OA aseptic loosening. 43 In our study patients with inflammatory arthritis were generally excluded. Although there is no direct comparison, it might be assumed that endotoxin levels depend to a greater extent on the presence of inflammatory diseases than on the origin of material. However, even the low endotoxin levels might contribute to aseptic loosening.
Regarding the limitations of this study, using OA material as control tissues is discussed controversial and suggestions have been made to use other control tissues harvested from "healthy" patients or from stable endoprostheses. 13 However, carefully chosen inclusion and exclusion criteria of patients might also improve OA material as gold standard. Divergent data regarding, for example, higher TNF-a expression levels in control tissues were observed in studies which did not exclude inflammatory diseases. 4 An "improved gold standard" which was used in this study might lead to a clearer picture about aseptic loosening. Further studies are required as expression levels in aseptic implant loosening seem to be more patient background dependent than assumed.
Although it might have been of importance to concentrate on the type and/or amount of wear we instead chose to concentrate on a group of patients undergoing the same type of medical problem and tried to integrate this data into a full picture. Interindividual differences between patients may play a role in aseptical loosening irrespective of the different degrees of particle activation caused by different materials. 44 In conclusion, we have examined PPTs with an "improved gold standard" and found ALP, COL1A, MMP-13, RANK, RANKL, and TRAP expressions to be increased whereas OPG expressions were decreased significantly compared to the control. We have described new and important findings regarding molecular components of PPTs which need to be further evaluated.
